BlackRock Advisors’s PTC Therapeutics PTCT Stock Holding History

BlackRock Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.84M	Sell	443,917 -295,126	-40%	-$3.1M	﹤0.01%	1147
2016 Q3	$10.4M	Sell	739,043 -3,668	-0.5%	-$29.8K	0.01%	848
2016 Q2	$5.21M	Buy	742,711 +11,278	+2%	+$82.7K	0.01%	1090
2016 Q1	$4.71M	Buy	731,433 +225,467	+45%	+$3.91M	﹤0.01%	1121
2015 Q4	$16.4M	Buy	505,966 +11,568	+2%	+$340K	0.02%	617
2015 Q3	$13.2M	Buy	494,398 +37,597	+8%	+$1.61M	0.01%	665
2015 Q2	$22M	Buy	456,801 +84,237	+23%	+$4.91M	0.02%	499
2015 Q1	$22.7M	Buy	372,564 +72,764	+24%	+$4.44M	0.02%	512
2014 Q4	$15.5M	Buy	299,800 +288,485	+2,550%	+$12.7M	0.02%	647
2014 Q3	$498K	Sell	11,315 -30,498	-73%	-$954K	﹤0.01%	1985
2014 Q2	$1.09M	Sell	41,813 -39,616	-49%	-$848K	﹤0.01%	1438
2014 Q1	$2.13M	Sell	81,429 -75,371	-48%	-$2.03M	﹤0.01%	1163
2013 Q4	$2.66M	Buy	156,800 +700	+0.4%	+$12.3K	﹤0.01%	1104
2013 Q3	$3.35M	Buy	+156,100	New	+$2.71M	﹤0.01%	1058

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

BlackRock Advisors's PTCT Position: Q4 2016 in Review

BlackRock Advisors reduced its PTC Therapeutics (PTCT) stake by 40% in Q4 2016, selling an estimated $3.1M and leaving 443,917 shares worth $4.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

BlackRock Advisors first reported a position in PTCT in Q3 2013 and has held it in 14 quarters since. The position peaked at $22.7M in Q1 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

BlackRock Advisors held 443,917 shares of PTC Therapeutics worth $4.84M as of Q4 2016.
BlackRock Advisors sold 295,126 PTC Therapeutics shares in Q4 2016, an estimated $3.1M.
PTC Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1147 holding.
BlackRock Advisors first reported a position in PTC Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Advisors's PTC Therapeutics position peaked at $22.7M in Q1 2015.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.